Cargando…

Lower Loading Dose of Prasugrel Compared with Conventional Loading Doses of Clopidogrel and Prasugrel in Korean Patients Undergoing Elective Coronary Angiography: A Randomized Controlled Study Evaluating Pharmacodynamic Efficacy

BACKGROUND AND OBJECTIVES: Although prasugrel allows for rapid and potent platelet inhibition, the efficacy and safety of lower doses of prasugrel for patients of East Asian ethnicity has not yet been investigated. We compared the effect of a lower loading dose (LD) of prasugrel with conventional LD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Dong Hyun, Kim, Moo Hyun, Guo, Long Zhe, Park, Min Kyu, Yi, So Jeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248610/ https://www.ncbi.nlm.nih.gov/pubmed/25469140 http://dx.doi.org/10.4070/kcj.2014.44.6.386

Ejemplares similares

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions
por: Kumari, Priti, et al.
Publicado: (2018)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms
por: Lee, Dongwhane, et al.
Publicado: (2018)

Low-Dose Prasugrel in Treatment of Cerebral Aneurysms
por: Kang, Hyun-Seung
Publicado: (2018)

Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial
por: Lee, Dong-Hyun, et al.
Publicado: (2013)

Successful Prasugrel Rescue Therapy in Clopidogrel Resistant Patients Who Had Recurrent Stent Thrombosis of Drug-Eluting-Stent: The Role of Prasugrel in Clopidogrel Nonresponders
por: Lee, Seung-Hyun, et al.
Publicado: (2013)

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
por: Angiolillo, Dominick J., et al.
Publicado: (2021)

Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention
por: Jin, Han-Young, et al.
Publicado: (2014)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months
por: Lee, Dongwhane, et al.
Publicado: (2019)

Pharmacodynamic assessment of prasugrel and clopidogrel in patients with non-cardioembolic stroke: a multicenter, randomized, active-control clinical trial
por: Yamaguchi, Takenori, et al.
Publicado: (2019)

Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment
por: Shoji, Satoshi, et al.
Publicado: (2020)

A Japanese Dose of Prasugrel versus a Standard Dose of Clopidogrel in Patients with Acute Myocardial Infarction from the K-ACTIVE Registry
por: Mori, Hiroyoshi, et al.
Publicado: (2022)

Bleeding events and maintenance dose of prasugrel: BLESS pilot study
por: Carrabba, Nazario, et al.
Publicado: (2016)

Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low‐Dose Prasugrel or Clopidogrel
por: Crimi, Gabriele, et al.
Publicado: (2019)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
por: Koyabu, Yota, et al.
Publicado: (2019)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

The use of CytoSorb® in a prasugrel‐loaded patient undergoing emergent coronary artery bypass graft surgery
por: Moresco, Erich, et al.
Publicado: (2023)

Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial
por: Jin, Cai-De, et al.
Publicado: (2021)

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Prasugrel-Induced Hypersensitivity Skin Reaction
por: Kim, Soo-Han, et al.
Publicado: (2014)

Prasugrel for Secondary Prevention of Thrombotic Stroke
por: Yagita, Yoshiki
Publicado: (2023)

Review of Prasugrel for the Secondary Prevention of Atherothrombosis
por: Spinler, Sarah A., et al.
Publicado: (2009)

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
por: Varenhorst, Christoph, et al.
Publicado: (2009)

Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
por: Olechowski, Bartosz, et al.
Publicado: (2016)

The Effect of Ticagrelor on Endothelial Function Compared to Prasugrel, Clopidogrel, and Placebo: A Systematic Review and Meta-Analysis
por: Guan, Baoyi, et al.
Publicado: (2022)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
por: Wang, Zhe, et al.
Publicado: (2020)

Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel
por: Motovska, Zuzana, et al.
Publicado: (2009)

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel
por: Geisler, Tobias, et al.
Publicado: (2015)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
por: Hajsadeghi, Shokoufeh, et al.
Publicado: (2016)

Long‐Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST‐Segment–Elevation Myocardial Infarction
por: Cassese, Salvatore, et al.
Publicado: (2020)

Prasugrel for the treatment of patients with acute coronary syndrome
por: Marzot, Filippo, et al.
Publicado: (2009)

TRITON and Beyond: New Insights into the Profile of Prasugrel
por: Jakubowski, Joseph A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rrih0lve7t89qh3ahvhpsiej1c